[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340565-105":59,"doc-detail-340565-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","role-of-bispecific-antibodies-in-gastroenteropancreatic-neuroendocrine-neoplasms-gep-nens-review-of-literature","Role of Bispecific Antibodies in Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) - Review of Literature","","Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) represent a heterogeneous disease group with rising incidence over recent decades. Although treatment options have advanced, resistance to multiple therapies creates substantial management difficulty. Bispecific antibodies (BsAbs) enable simultaneous receptor targeting and immune engagement within the tumor microenvironment, representing a major therapeutic development. This review summarizes current BsAbs under development or clinical testing for GEP-NENs, including mechanisms, trial outcomes, toxicities, and future studies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/role-of-bispecific-antibodies-in-gastroenteropancreatic-neuroendocrine-neoplasms-gep-nens-review-of-literature/340565/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/role-of-bispecific-antibodies-in-gastroenteropancreatic-neuroendocrine-neoplasms-gep-nens-review-of-literature/340565.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What makes gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) challenging to treat?","Question",{"text":112,"@type":113},"GEP-NENs are heterogeneous and their incidence has increased. Despite therapeutic advances, resistance to multiple treatments limits improved outcomes, especially in high-grade subgroups.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do bispecific antibodies (BsAbs) work in GEP-NENs?",{"text":117,"@type":113},"BsAbs have two binding sites that can engage two different targets or two epitopes on the same antigen. They can connect immune cells to tumor cells and block dual signaling pathways to promote cytotoxic effects.",{"name":119,"@type":110,"acceptedAnswer":120},"Which bispecific antibody example is highlighted, and what is its target?",{"text":121,"@type":113},"Tidutamab (XmAb18087) is presented as an SSTR2 × CD3 bispecific antibody. It combines an SSTR2 binding domain with a T-cell (CD3) binding domain.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340565,1790112474,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Role of Bispecific Antibodies in Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs):  \nReview of Literature  \nAmr Mohamed1 , Mai Elhawi2 , Marcus Trybula1, Mohamed Elshawy3 , Sakti Chakrabarti1, Eva Selfridge1 and Sylvia L Asa4  \n1Division of Medical Oncology, Department of Medicine, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA. 2 Department of Clinical Oncology, Ain Shams University Hospital, Cairo, Egypt. 3 Department of Surgery, Cleveland Clinic Foundation, Cleveland, OH, USA. 4 Department of Pathology, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.  \nClinical Medicine Insights: Oncology  \nVolume 18: 1–6  \n© The Author(s) 2024  \nArticle reuse guidelines: [sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/11795549241285213](DOI: 10.1177/11795549241285213)  \n|  |  |\n| --- | --- |\n| ABSTRACT: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are a heterogeneous group of neoplasms with an increasing incidence in the last few decades. Despite therapeutic advances in the management of GEP-NENs, resistance to many of these treatments has made their management a great challenge. One of the most recent advances in oncologic therapy is targeting multiple receptors simultaneously and engaging immune cells in the tumor microenvironment through bispecific antibodies (BsAbs) . Since the FDA approval of the anti-CD3 × anti CD19 BsAb blinatumomab, for management of B-cell acute lymphoblastic leukemia, around a hundred different BsAbs have been developed and tested in various clinical trials. In this article, we review the current development of BsAbs developed or being currently tested for the management of GEP-NENs, their mechanism of action, current results from ongoing trials, toxicities, and upcoming trials.\u003Cbr>KEywoRdS: Gastroenteropancreatic neuroendocrine tumors, bispecific antibodies |  |\n| RECEIVEd: September 25, 2023. ACCEPTEd: September 1, 2024.\u003Cbr>TyPE: Review\u003Cbr>FuNdING: The author(s) received no financial support for the research, authorship, and/or publication of this article. | dECLARATIoN oF CoNFLICTING INTERESTS: The author(s) declared no potential\u003Cbr>conflicts of interest with respect to the research, authorship, and/or publication of this article.\u003Cbr>CoRRESPoNdING AuTHoR: Amr Mohamed, Division of Medical Oncology, Department of Medicine, University Hospitals, Seidman Cancer Center, Case Western Reserve University,\u003Cbr>11100 Euclid Ave, Cleveland OH 44106, USA. Email: [amr.mohamed@uhhospitals.org](amr.mohamed@uhhospitals.org) |\n| Introduction | First described by Nisonoff and co-workers more than |\n| Gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) are heterogeneous neoplasms originating from neu- | 50 years ago,4 BsAbs can be divided based on their function into BsAbs that act directly on their targets by neutralizing/ |\n| roendocrine secretory cells of the gastroenteropancreatic | activating them, and BsAbs that target specificity to deliver a |\n| system. Their incidence has risen in the last decade from 1.9 | therapeutically active moiety, such as a toxin. BsAbs tend to |\n| cases per 100 000 to 6.8 cases per 100 000 in the United States. | be either “IgG-like,” large molecules containing an Fc region |\n| They are classified according to their histological differentia- | and its related effector function while resembling conven- |\n| tion into well-differentiated neuroendocrine tumors (NETs) | tional antibodies and having a longer serum half-life, or “non- |\n| that are divided into 3 grades based on their proliferative activ- | IgG-like,” lacking the Fc region as, smaller molecules that |\n| ity, and poorly differentiated neuroendocrine carcinomas | exhibit enhanced tissue penetration but a shorter half-life. |\n| (NECs) that are, by definition, high grade.1 Despite the sig- | Over 100 BsAb formats have been developed into techno","cbCaiuTIhulzKlcH","https://ap.wps.com/l/cbCaiuTIhulzKlcH","pdf",947213,"English","# Introduction\n## Current bispecific antibody formats and mechanisms\n# Current bispecific antibodies in GEP-NENs\n## Tidutamab (XmAb18087) (SSTR2 × CD3)","[{\"question\":\"What makes gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) challenging to treat?\",\"answer\":\"GEP-NENs are heterogeneous and their incidence has increased. Despite therapeutic advances, resistance to multiple treatments limits improved outcomes, especially in high-grade subgroups.\"},{\"question\":\"How do bispecific antibodies (BsAbs) work in GEP-NENs?\",\"answer\":\"BsAbs have two binding sites that can engage two different targets or two epitopes on the same antigen. They can connect immune cells to tumor cells and block dual signaling pathways to promote cytotoxic effects.\"},{\"question\":\"Which bispecific antibody example is highlighted, and what is its target?\",\"answer\":\"Tidutamab (XmAb18087) is presented as an SSTR2 × CD3 bispecific antibody. It combines an SSTR2 binding domain with a T-cell (CD3) binding domain.\"}]","Role of Bispecific Antibodies in Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) - Review of Literature | PDF",1790037342,15,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44e00c882e6ab3bfe17d2f5c6a22437c.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c1b619c87da574c1f75048a41246e59.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/748a71a255050d62f3f211bd61355ef5.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5245e00a4e48df60b1cce2915cf68c4d.webp",980,1385]